An Act Requiring Side Effect Disclosures On State-funded Advertisements For Vaccines.
Summary
HB06561 would amend the Connecticut General Statutes to require that any advertisement for a vaccine that is funded by the state include a conspicuous disclosure of any potential side effects of that vaccine. The bill is narrowly focused on advertising content rather than vaccine access, coverage, or clinical practice, and it applies only to advertisements paid for with state funds.
In practical terms, the measure would impose a new disclosure requirement on state-funded public health messaging or promotional materials related to vaccines. Agencies or contractors producing such advertisements would need to ensure that side effects are clearly and prominently presented, which could affect the design, wording, and approval process for vaccine-related outreach materials.
Impact
The bill would create a new statutory requirement for state-funded vaccine advertisements, likely affecting public health agencies, communications vendors, and any state-supported vaccination campaigns. It would not directly regulate vaccine manufacturers or private advertisers, but it would require state-funded promotional materials to include conspicuous warnings about potential side effects, potentially changing how the state communicates vaccine benefits and risks.
Sentiment
No committee transcripts or recorded votes were provided, so there is no direct evidence of legislative debate or formal support/opposition in the available record. Based on the bill text alone, the proposal appears to reflect a precautionary or transparency-focused approach to vaccine advertising, emphasizing disclosure of risks alongside promotional messaging.
Contention
The main point of contention likely concerns whether requiring side-effect disclosures in state-funded vaccine advertisements would improve informed decision-making or instead discourage vaccination by emphasizing risks. Supporters would likely frame the bill as a transparency measure, while opponents may argue it could create misleading impressions, complicate public health messaging, or undermine confidence in vaccines. Because no discussion transcripts are available, specific legislators or stakeholder positions cannot be identified from the record provided.